Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Involvement of tissue transglutaminase in endothelin 1-induced hypertrophy in cultured neonatal rat cardiomyocytes.

Li X, Wei XL, Meng LL, Chi MG, Yan JQ, Ma XY, Jia YS, Liang L, Yan HT, Zheng JQ.

Hypertension. 2009 Oct;54(4):839-44. doi: 10.1161/HYPERTENSIONAHA.109.130161. Epub 2009 Jul 27.

PMID:
19635990
2.

Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA.

Huebner JL, Johnson KA, Kraus VB, Terkeltaub RA.

Osteoarthritis Cartilage. 2009 Aug;17(8):1056-64. doi: 10.1016/j.joca.2009.02.015. Epub 2009 Mar 24.

3.

Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation.

Strnad P, Siegel M, Toivola DM, Choi K, Kosek JC, Khosla C, Omary MB.

FEBS Lett. 2006 Apr 17;580(9):2351--2357.

4.

Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy.

Johnson KA, van Etten D, Nanda N, Graham RM, Terkeltaub RA.

J Biol Chem. 2003 May 23;278(21):18824-32. Epub 2003 Feb 26.

5.

Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation.

Small K, Feng JF, Lorenz J, Donnelly ET, Yu A, Im MJ, Dorn GW 2nd, Liggett SB.

J Biol Chem. 1999 Jul 23;274(30):21291-6.

Supplemental Content

Loading ...
Support Center